Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | Precision medicine in pediatric ALL

Sarah Tasian • 4 Jun 2023
ASCO 2023
Acute Lymphoblastic Leukemia Leukemia

Sarah Tasian, MD, The Children’s Hospital of Philadelphia, Philadelphia, PA, discusses precision medicine in the management of pediatric acute lymphoblastic leukemia (ALL), highlighting prognostic indicators such as cytogenetics and MRD status following induction chemotherapy. Dr Tasian follows by sharing strategies currently under evaluation such as targeted agents and immunotherapies. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Sarah Tasian

1:16
Pediatric leukemia at ASCO 2023
Sarah Tasian • 4 Jun 2023
0:54
Clinical responses of pediatric patients with R/R acute leukemia treated with aza/ven
Sarah Tasian • 16 Apr 2023
0:56
Improving therapeutic approaches for patients with Ph-like ALL & the importance of disease biology
Sarah Tasian • 16 Apr 2023
0:42
Exploring the potential role of immunotherapy in Ph-like ALL and novel targets of interest
Sarah Tasian • 16 Apr 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals